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Abstract
Aims/hypothesis Type 1 diabetes is a T cell-mediated autoimmune disease characterised by the destruction of beta cells in the
islets of Langerhans, resulting in deficient insulin production. B cell depletion therapy has proved successful in preventing
diabetes and restoring euglycaemia in animal models of diabetes, as well as in preserving beta cell function in clinical trials in
the short term. We aimed to report a full characterisation of B cell kinetics post B cell depletion, with a focus on pancreatic islets.
Methods Transgenic NOD mice with a human CD20 transgene expressed on B cells were injected with an anti-CD20 depleting
antibody. B cells were analysed using multivariable flow cytometry.
Results There was a 10 week delay in the onset of diabetes when comparing control and experimental groups, although the final
difference in the diabetes incidence, following prolonged observation, was not statistically significant (p = 0.07). The co-
stimulatory molecules CD80 and CD86 were reduced on stimulation of B cells during B cell depletion and repopulation. IL-
10-producing regulatory B cells were not induced in repopulated B cells in the periphery, post anti-CD20 depletion. However, the
early depletion of B cells had a marked effect on T cells in the local islet infiltrate. We demonstrated a lack of T cell activation,
specifically with reduced CD44 expression and effector function, including IFN-γ production from both CD4+ and CD8+ Tcells.
These CD8+ T cells remained altered in the pancreatic islets long after B cell depletion and repopulation.
Conclusions/interpretation Our findings suggest that B cell depletion can have an impact on Tcell regulation, inducing a durable
effect that is present long after repopulation.We suggest that this local effect of reducing autoimmune Tcell activity contributes to
delay in the onset of autoimmune diabetes.
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Abbreviations
Breg Regulatory B cell
hCD20 Human CD20
LPS Lipopolysaccharide
PLN Pancreatic lymph node
PMA Phorbal 12-myristrate-13-acetate
SPICE Simplified presentation of incredibly
complex evaluations
T2 Transitional 2
Treg Regulatory T cell
TRM Tissue-resident memory
Introduction
Type 1 diabetes, an organ-specific autoimmune disease with a
multifactorial aetiology, is characterised by the immune-
mediated destruction of beta cells in pancreatic islets, resulting
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in insufficient insulin production [1]. Although relatively few
immunotherapeutic strategies delay the loss of islet beta cell
function, depleting B cells using anti-CD20 monoclonal anti-
body (rituximab) has delayed C-peptide loss within the first
year [2]. Follow-up studies demonstrated that during depletion
there was a decreased antibody response to new and recall
antigens [3] but that rituximab suppressed anti-insulin autoan-
tibodiesmore than anti-GAD, -IA-2 and -ZnT8 autoantibodies
[4]. Interestingly, during depletion, T cell proliferative re-
sponses to islet antigens increased, particularly in responders
to B cell depletion therapy [5]. In addition, the frequencies of
autoreactive B cells, judged by islet autoantibody-producing
cell clones and by polyreactive B cells, as shown by Hep-2
cell reactivity, were unchanged a year after rituximab treat-
ment and reconstitution [6].
In NOD mice, agents effecting timed depletion of B cells
prevent diabetes [7–11] and reverse disease after onset [7, 8,
12]. These include anti-human CD20 antibody in human
CD20 (hCD20)/NOD transgenic mice (in which the human
gene MS4A1, encoding hCD20, is expressed), anti-mouse
CD20 ant ibody, ant i -CD22 ant ibody coupled to
immunotoxin, B-Lys/BAFF neutralisation and BCMA-Fc
chimerised protein [7, 8, 12]. While these strategies all influ-
ence development of diabetes, there are important differences
in the effector mechanisms. The many factors determining
therapeutic efficacy are not fully characterised. For example,
the duration of B cell depletion may be important: monoclonal
anti-CD20 that depletes B cells transiently (repopulation by
5 weeks) was not effective in preventing or protecting against
diabetes [13]. Thus, it is important to understand kinetics and
immunological effects following anti-B cell treatment with
such agents.
In a mouse model, using a strategy and antibody similar to
rituximab, responses of pathogenic CD4+ T cells were greater
in the short term [14]. This recapitulated the finding in humans
where T cell responses increased [5]. However, some poten-
tially regulatory subsets of cells, including transitional-zone 2
(T2) B cells, T cells and Gr1+ cells, were increased following
repopulation after depletion [15]. Thus, the protection con-
ferred by treatment with anti-CD20 relates not only to the
depletion of effector B cells but also to the increase of regu-
latory populations. The combination of anti-CD20 and oral
administration of anti-CD3 had a synergistic effect in
hCD20/NOD mice, also related to increased frequency and
function of regulatory T cells [16].
In this study, we focused on characterising the effects of B
cell depletion on peripheral B cells and the characteristics of
the cellular infiltrate in the islets of Langerhans in the hCD20/
NOD mouse. We hypothesised that B cell depletion alters the
islet immune infiltrate, contributing to protection from
diabetes.
Methods
Mice Human CD20 (hCD20) transgenic mice on a BALB/c
background (in which the human gene MS4A1, encoding
hCD20, is expressed) [17] were backcrossed to the NOD
•
•
•
•
•
• γ
•
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genetic backgroundmore than ten generations, and designated
hCD20/NOD mice [7]. Mice were maintained at Cardiff
University in specific pathogen-free isolators or scantainers.
Mice received water and food ad libitum and were housed in a
12 h dark–light cycle. Animal experiments were conducted in
accordance with United Kingdom Animals (Scientific
Procedures) Act, 1986 and associated guidelines.
Diabetes incidence Mice were monitored weekly for glycos-
uria (Bayer Diastix) from 12 weeks of age. Diabetes was con-
firmed by blood glucose levels >13.9 mmol/l.
Anti-CD20 treatment Female hCD20/NOD mice, aged 6–8 or
12–15 weeks were chosen at random to receive anti-hCD20
antibody (clone 2H7; Bio-XCell [West Lebanon, NH, USA])
or control IgG2b antibody (clone MPC-11; Bio-XCell [7, 14,
15]). An i.v. injection of 500 μg of antibody in 200 μl of saline
solution (154mmol/l NaCl) was followed at 3 day intervals by
three i.p. injections (modified from [7]).
Cell preparations Pancreatic lymph nodes (PLNs) were
disruptedmechanically with a 30G needle. Bone-marrow cells
were flushed out from the hind legs (femur and tibia). Spleens
were homogenised and erythrocytes were lysed. Pancreases
were inflated with collagenase P solution (Roche, Burgess
Hill, UK) in Hanks’ Balanced Salt Solution (HBSS) via the
common bile duct, followed by collagenase digestion with
shaking at 37°C for 10 min. Islets were isolated by
Histopaque density centrifugation (Sigma-Aldrich,
Gillingham, UK), hand-picked under a dissecting microscope
and trypsinised to generate single-cell suspensions. Islet cells
were rested at 37°C, 5% CO2 in complete Iscove’s Modified
Dulbecco’s Medium (IMDM) overnight, before stimulation
for intracellular staining.
Flow cytometry Single-cell suspensions were incubated with
TruStain (anti-mouse CD16/32; Biolegend [London, UK]) for
10 min at 4°C, followed by fluorochrome-conjugated mono-
clonal antibodies against cell surface markers for 30 min at
4°C. Multivariable flow cytometry was carried out using
monoclonal antibodies: CD4-FITC (GK1.5 [1:200]), CD8-
PE-594 (53-6.7 [1:800]), CD103-BV510 (2E7 [1:100]), PD-
1-BV785 (29F.1A12 [1:200]), IFN-γ-BV711 (XMG1.2
[1:100]), CD107a-PeCy7 (1D4B [1:200]), CD69-AF700
(H1.2F3 [1:100]), TGF-β-BV421 (TW7-16B4 [1:100]),
CD38-FITC (90 [1:200]) and CD86-PeCy7 (PO3 [1:200])
(all from Biolegend); IL-10-APC (JES5-16E3 [1:200]),
CD1d-BV510 (1B1 [1:200]), CD21-PE-594 (7G6 [1:1000]),
CD23-BV711(B3B4 [1:800]), CD24-BV650 (M1/69
[1:400]), CD3-BV786 (145-2C11 [1:100]) and CD80-
BV650 (16-10A1 [1:100]) (all from BD Biosciences,
Reading, UK); CD19-efluor780 (eBio1D3 [1:800]), CD5-
PeCy7 (53-7.3 [1:200]), IL-6-PerCP-Cy5.5 (MP5-20F3
[1:200]) and CD44-PerCP-Cy5.5 (IM7 [1:1600]) (all from
eBiosciences,Waltham,MA,USA). All antibodies were titrat-
ed before use. Dead cells were excluded from the analysis by
Live/Dead exclusion (Invitrogen, Paisley, UK). For intracel-
lular cytokine analysis, splenocytes were either unstimulated
or stimulated for 24 h with 5 μg/ml lipopolysaccharide (LPS)
(Sigma-Aldrich) or 5 μg/ml anti-CD40 (Bio-XCell) and
washed. After an overnight resting period, 3 h before antibody
staining, phorbal 12-myristrate-13-acetate (PMA) (50 ng/ml),
ionomycin (500 ng/ml) and monensin (3 μg/ml) (all from
Sigma-Aldrich) were added to the cells. CD107a antibody
was added prior to stimulation, as previously described [18].
Fc receptors were blocked using TruStain and, after extracel-
lular staining, cells were fixed using fixation/permeabilisation
kit (BD Biosciences) according to the manufacturer’s instruc-
tions and then stained for intracellular cytokines or appropriate
isotype controls. Cell suspensions were acquired on
LSRFortessa (FACSDIVA software; BD Biosciences). All
analysis was performed using Flowjo software (Tree Star,
Ashland, OR, USA).
Statistical analysis No data were excluded from the analysis.
Statistical analysis was performed using GraphPad Prism
version 5 (GraphPad Software, SanDiego, CA, USA). For islet
T cells, multivariable flow cytometric analysis was performed
using SPICE (Simplified Presentation of Incredibly Complex
Evaluations) version 5.1 (http://exon.niaid.nih.gov).
Comparison of distributions was performed using the Mann–
WhitneyU test and a partial permutation test [19]. For diabetes
incidence, the Gehan–Breslow–Wilcoxon test was used. All
other data were analysed by the Mann–Whitney U test.
Results
Kinetics of B cell subset repopulation after anti-CD20 treat-
ment hCD20/NOD mice were treated with 2H7 or isotype
control antibodies at 6–8 weeks (little insulitis) or 12–
15weeks of age (established insulitis) (Fig. 1a). Wemonitored
disease progression in mice that were B cell-depleted at 6–
8 weeks old. Diabetes was first seen in the treated mice at
29 weeks of age, delayed by 10 weeks, and incidence was
reduced in the 2H7-treated groups (ESM Fig. 1). At the time
of diabetes onset in the experimental group, 63% of the con-
trol mice that ultimately developed disease were diabetic, al-
though the difference at the termination of the experiment was
not statistically significant (p = 0.07). This delayed incidence
was in keeping with our previously published observation [7].
B cells were successfully depleted in both age groups and had
fully repopulated the spleen by 12 weeks post depletion (Fig.
1b, e). No change was observed in the numbers of CD4 or
CD8 T cells during depletion or repopulation (Fig. 1c, d, f, g).
B cell depletion in PLNs (Fig. 1i, l), vs spleen (Fig. 1h, k), was
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prolonged. B cells were not fully depleted in the bonemarrow,
compared with other lymphoid tissues (Fig. 1j, m).
Kinetics of repopulation of B cell regulatory subsets after anti-
CD20 treatment The various B cell depletion methods target
different B cell zones in the spleen [7, 20]. Splenic B cell
populations were mostly depleted 24 h after 2H7 treatment
(Fig. 2a) and B cell numbers were significantly reduced
(Fig. 2b–g). The marginal zone (Fig. 2h, k) and T2 (Fig.
2i, l), enriched in regulatory B cells (Bregs), were more
successfully depleted than the follicular zone after
anti-CD20 treatment (Fig. 2j, m), indicating that Bregs
were not spared during depletion. Follicular zone and T2
B cells repopulated before the marginal zone. At 12 or
30 weeks after B cell depletion, there was no increase in
T2 cell numbers (data not shown). This contrasts with our
previous findings of increased numbers of T2 cells in older
diabetic mice, which became normoglycaemic after B cell
dep le t ion wi th an t i -CD20 ant ibody [7] , o r in
normoglycaemic 30-week-old mice treated with anti-CD22
depleting antibody [8], indicating that Bregs with T2 phe-
notype were not enriched after B cell repopulation. These
differences may be due to the use of younger and non-
diabetic mice in our current study.
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Fig. 1 Characterisation of anti-CD20 depletion treatment. hCD20/NOD
mice aged 6–8 (b–d, h–j) or 12–15 weeks (e–g, k–m) were injected with
2H7 anti-CD20 antibody (grey lines/squares in b–g) or IgG control anti-
body (black lines/circles in b–g). Diabetes progression was monitored
and lymphocyte populations were analysed by flow cytometry at different
time points after antibody depletion. (a) Schematic representation of in-
jection regimen. (b–g) Cell numbers for splenic CD19+ B cells (b, e),
CD8+ T cells (c, f) and CD4+ T cells (d, g). Data are expressed as mean ±
SEM. Each time point includes a minimum of six mice from at least two
independent experiments. (h–m) Percentage of B cells depleted or
repopulated (calculated as individual numbers from each 2H7-treated
mouse/mean number from all control antibody-treated mice) at various
time points for different lymphoid organs: spleen (h, k), pancreatic lymph
node (i, l), bone marrow (j, m). Horizontal lines indicate medians.
**p < 0.01 and ***p < 0.001 (Mann–Whitney U test, control vs 2H7)
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B cell depletion does not enrich for B cells producing regula-
tory cytokines or reduce inflammatory B cells after repopula-
tion There were significantly fewer IL-10+ B cells in spleens
from mice treated with 2H7 vs control antibody, unstimulated
or following stimulation with LPS or anti-CD40, at either 8 or
12 weeks post depletion, (Fig. 3b, d). This difference was
more marked at 12 weeks, when the B cells were repopulated.
Moreover, at 30 weeks post depletion, there were still fewer
IL-10+ B cells in 2H7-treated mice, unstimulated or stimulated
with anti-CD40, than in age-matched control antibody-treated
mice (ESM Fig. 2). We observed no enrichment of IL-10+ B
cells in the marginal zone or T2 compartments (data not
shown) or in CD1dhiCD5+ or CD24hiCD38hi Breg cells dur-
ing or after depletion (ESM Fig. 3).
We analysed the TGF-β response, as B cell regulation can
occur via TGF-β [21, 22]. In mice aged 6–8 weeks, the num-
ber of TGF-β+ B cells was significantly increased 8 weeks
post depletion, albeit at small percentages overall (Fig. 3c, e).
Differences were not maintained at 12 weeks post treatment in
either of the age groups. Therefore, anti-CD20 treatment did
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Fig. 2 Kinetics of B cell regulatory markers after anti-CD20 antibody
treatment. hCD20/NODmice aged 6–8 weeks (b–d, h–j) or 12–15 weeks
(e–g, k–m) were injected with 2H7 anti-CD20 antibody (grey lines/
squares in b–g) or IgG control antibody (black lines/circles in b–g) and
total splenocytes were analysed. CD19+ B cell populations were identi-
fied by flow cytometry at different time points after depletion. (a)
Representative flow plots (24 h) of spleen compartments marked by
CD21 and CD23 (marginal zone [MZ: CD21hiCD23low], T2
[CD21hiCD23hi]) and follicular zone [FO: CD21lowCD23hi], showing
flow cytometric gating of control IgG- and 2H7-treated mice (aged 6–
8 weeks). (b–g) Number of B cells fromMZ (b, e), T2 (c, f) and FO (d, g)
spleen compartments. (h–m) Percentage of B cells depleted or
repopulated for MZ (h, k), T2 (i, l) and FO (j, m) spleen compartments
(calculated as individual numbers from each 2H7-treated mouse/mean
number from all control antibody-treated mice). Horizontal lines indicate
medians. All surfacemarkers are shown for cells that were gated on viable
CD3−CD19+. Data are expressed as mean ± SEM. Each time point in-
cludes a minimum of six mice from at least two independent experiments.
**p < 0.01 and ***p < 0.001 (Mann–Whitney U test, control vs 2H7)
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not promote a sustained Breg phenotype either during or long
after repopulation of the spleen, in either of the age groups of
mice studied. We examined the proinflammatory cytokine-
producing B cell populations. In the younger mice, 2H7 and
control antibody treatment produced little change in the num-
ber of IL-6+ B cells, with or without LPS or anti-CD40 stim-
ulation; these mice had significantly fewer IL-6+ B cells at
8 weeks post depletion but at 12 weeks this effect was lost
and stimulation with anti-CD40 caused an increase in IL-6+ B
cells (ESM Fig. 4).
B cell co-stimulatory markers are downregulated during B cell
depletion To test the repopulating B cells for altered co-
stimulatory potential, we studied the expression of CD86
and CD80 on B cells following stimulation with LPS or
anti-CD40 (Fig. 4). 2H7-treated mice in both age groups
expressed significantly fewer CD19+CD80+ B cells when
stimulated with anti-CD40 during regeneration at 8 weeks
(Fig. 4b, d); this difference was less marked at 12 weeks.
More strikingly, significantly fewer B cells expressed CD86
during regeneration at 8 weeks, following the different stimuli
used in both age groups of mice (Fig. 4c, e). This reduction
was maintained at 12 weeks (when cells were fully
repopulated), particularly following stimulation with anti-
CD40, in mice aged 6–8 weeks. Unstimulated B cells from
2H7- and control antibody-treated mice at repopulation
(12 weeks) were used as antigen-presenting cells in a prolif-
eration assay to stimulate insulin-peptide-reactive CD8+ T
cells as responders. We observed no difference in carboxyflu-
orescein succinimidyl ester (CFSE) dilution as a measure of
proliferation of these CD8+ T cells (data not shown). At
30 weeks of age, whether unstimulated or stimulated, B cells
expressing CD86 in both age groups were comparable, al-
though fewer B cells expressed CD80 when stimulated with
anti-CD40 in 2H7-treated mice (ESM Fig. 5).
Effect of anti-CD20 on B cells in pancreatic islets We next
investigated the effects of anti-CD20 on local pancreatic islet
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Fig. 3 Repopulated B cells are
not enriched for IL-10. B cells
from the spleen were analysed for
intracytoplasmic cytokines 8 and
12 weeks post treatment with
control IgG (black circles) or 2H7
anti-CD20 depleting antibody
(white squares) in mice aged 6–8
(b, c) or 12–15 weeks (d, e). B
cells were either unstimulated or
stimulated with 5 μg/ml LPS or
anti-CD40. (a) Representative
flow plots from 12 weeks post
depletion. (b–e) Frequency of IL-
10-producing B cells (b, d) and
TGF-β-producing B cells (c, e) 8
and 12 weeks post depletion.
Horizontal lines represent the
medians. Each time point
includes a minimum of seven
mice, from at least two
independent experiments.
*p < 0.05, **p < 0.01 and
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B cells during B cell depletion and repopulation in mice aged
6–8 and 12–15 weeks. Significantly fewer B cells were isolat-
ed from the pancreatic islets of anti-CD20-treated mice in both
groups, as early as 24 h post antibody administration (Fig. 5a,
d and ESM Fig. 6a). At 12 weeks post treatment, B cells in the
islets of both groups had returned to the levels found in the
control antibody-treated mice. Consistent with B cells in the
spleen, a downregulation of IL-10 was observed (Fig. 5b, e).
There were fewer IL-10+ B cells in 2H7-treated mice aged 12–
15 weeks, at both 8 and 12 weeks post depletion (p < 0.01 at
12 weeks). Unlike splenocytes, we observed no difference in
islet TGF-β+ B cells following 2H7 vs control antibody treat-
ment (Fig. 5c, f). We further phenotyped islet B cells at 12 and
30 weeks after depletion in mice aged 6–8 weeks (Fig. 5g–l;
for representative staining, see ESM Fig. 6b). Multivariable
analysis demonstrated that, at both 12 and 30 weeks post
depletion, there was no overall change in B cell phenotype
or difference between the proportions of the B cell subsets.
However, individual populations of IL-10+ and TGF-β+ B
cells were significantly reduced 12 weeks post depletion,
confirming our earlier analysis of peripheral cells. At 30weeks
post depletion, no significant difference was seen in the fre-
quencies of the B cells within the islets, confirming that B
cells had fully repopulated. However, less CD44 expression
was noted, indicating lower activation.
Anti-CD20 treatment influences T cell populations in the islet
microenvironment B cell depletion has been shown to induce
peripheral regulatory T cells (Tregs) after B cell regeneration.
We observed no differences in CD4+ or CD8+ T cell numbers
in mouse islets following anti-CD20 vs control antibody treat-
ment (Fig. 6a–d), at any point during depletion (24 h, 8 weeks
and 12 weeks; for representative staining see ESM Fig. 7a) or
at 30 weeks post depletion (data not shown). Thus, B cell
depletion did not affect T cell homing to the pancreas.
However, the effect of anti-CD20 treatment on CD4+ and
CD8+ Tcells was significantly greater in islets frommice aged
6–8 weeks vs 12–15 weeks (Fig. 6e–l). In the younger mice,
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during B cell depletion and regeneration (8 and 12 weeks,
respectively) both IFN-γ+ (Fig. 6e, g) and, surprisingly, IL-
10+ (Fig. 6f, h) CD4+ T cells were significantly reduced. Islet-
infiltrating CD8+ T cells also significantly downregulated
IFN-γ production during B cell regeneration at 12 weeks
(Fig. 6i, k), accompanied by a decrease in CD107a expression
(Fig. 6j, l) representing cytotoxic degranulation on stimula-
tion, although this was not statistically significant. Both
IFN-γ and CD107a expression in CD8+ T cells from 12- to
15-week-old treated mice were comparable.
Multivariable analysis of CD4+ T cells revealed a shift in the
local proinflammatory environment We examined activation
(CD44, CD69, PD-1) and cytokine production (IFN-γ,
TGF-β, IL-10) of pancreatic CD4+ T cells during B cell re-
population (for representative staining, see ESM Fig. 7b). Islet
CD4+ T cells from anti-CD20 antibody-treated mice aged
6–8 weeks were examined at 12 weeks and 30 weeks after B
cell depletion, when complete B cell regeneration had oc-
curred (Fig. 7). We observed significant differences in CD4+
Tcell composition at 12 weeks post B cell depletion (p < 0.05)
(Fig. 7a, c), although CD4+ T cell subsets were comparable at
30 weeks (Fig. 7b, d). The CD4+ T cell subsets at 12 weeks
post treatment had a less-activated phenotype, characterised
by fewer CD44+CD4+ T cells, which lacked functional ex-
pression of IFN-γ; however, there was no enrichment of IL-
10+ or TGF-β+CD4+ T cells (Fig. 7e). At 30 weeks post de-
pletion, there were still significantly fewer IFN-γ+CD4+ T
cells in 2H7-treated mice than in control IgG-treated mice
(Fig. 7f). Here, the CD69 increase may be a result of altered
kinetics and an increase in new CD4+ T cells that home to the
tissue and encounter a proinflammatory environment.
B cell depletion affects islet-associated CD8+ T cells long after
treatmentWe next analysed the impact of B cell depletion on
local CD8+ T cells in the islets of hCD20/NOD mice aged
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antibody. (a, g) Number of CD4+
T cells and (d, j) number of CD8+
Tcells. Each point represents cells
isolated from all islets recovered
from individual pancreases. Black
lines/circles, control IgG; grey
lines/squares, 2H7. (b, e, h, k)
Cytokines in islet CD4 T cells:
percentage of IFN-γ+ (b, h) and
IL-10+ cells (e, k). (c, f, i, l)
Cytokine and cytotoxic markers
on pancreatic islet CD8 T cells:
percentage of cells positive for
cytokine IFN-γ (c, i) and
cytotoxic CD107a (f, l). Black
circles, control IgG; white
squares, 2H7. Data are
representative of a minimum of
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(Mann–WhitneyU test, control vs
2H7)
Diabetologia (2018) 61:1397–1410 1405
6–8 weeks, focusing on the islet environment during repopu-
lation (Fig. 8; see ESM Fig. 8 for representative staining).
Particularly striking, was the high influx of heterogeneous
CD8+ T cell subsets into the pancreatic islets after initial dam-
age has occurred [23, 24]. At 12 weeks post depletion, islet-
infiltrating CD8+ T cells significantly differed in their compo-
sition (Fig. 8a, c) and were characterised by a lack of effector
function typified by less CD44 expression coupled with de-
creased IFN-γ and CD107a production, confirming our earlier
observations (Fig. 8e) (p < 0.05). As with islet CD4+ T cells,
we observed an increase in CD69+CD8+ T cells in the 2H7-
treated mice, which may represent naive CD8+ T cell subsets
being activated locally.
At 30 weeks post treatment, islet CD8+ T cell subsets were
comparable; although there were fewer activated CD8+ T
cells, this was not statistically significant (Fig. 8b, d).
Interestingly, CD8+ T cells expressing CD103 and CD69,
which indicate a tissue-resident memory (TRM) CD8 T cell
phenotype and are associatedwith controlling tissue immunity
after infection [25], were enriched in the islets of 2H7-treated
mice (Fig. 8f).
Discussion
In the current study, we observed changes in the inflammatory
islet environment during B cell regeneration and these persisted
long after anti-CD20 treatment. We demonstrated a significant
decrease in effector function of CD4+ and CD8+ T cells, with a
reduction in IFN-γ production, correlated with a
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downregulation of activation markers. These changes were
more pronounced in mice aged 6–8 weeks vs 12–15 weeks,
possibly reflecting the difference in lymphocyte behaviour re-
cently demonstrated in islets in NOD mice before and after
insulitis [26]. B cell depletion also reduced the expression of
CD80 and CD86 on peripheral B cells when stimulated during
the B cell regeneration period in the hCD20/NOD mouse mod-
el.Moreover, B cells with a regulatory phenotype were depleted
in the periphery and were not increased following regeneration.
As reported previously, we demonstrated that anti-CD20
treatment, in this transgenic system, successfully targets the
B cells in peripheral and local tissue [7]. Although all B cell
populations were depleted, transitional- and marginal-zone B
cells were more susceptible (not due to different hCD20 ex-
pression, data not shown). Our work supports some previous
findings [5] but differs from other work indicating that the
follicular zone was targeted more readily [20, 27]. This may
be due to different mouse genetic background [27] and the
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different monoclonal antibody used [20]. Our data, consonant
with other studies, demonstrated the depletion of regulatory B
cell populations in the marginal zone and T2 compartments,
CD1dhiCD5+ and CD24hiCD38hi subsets, along with other B
cells (data not shown). B cells with regulatory potential were
not spared after B cell depletion. However, TGF-β+ B cells
were proportionally significantly increased during depletion,
although the percentages were small, whereas IL-10 produc-
tion from B cells was not enriched during B cell regeneration
under our experimental conditions. Furthermore, Breg subsets
were not enriched during regeneration. This corroborated our
earlier findings in the BDC2.5 transgenicmousemodel, show-
ing that CD1d− B cells are more protective than CD1d+ B
cells, dependent on cell–cell contact, but not IL-10 [14].
Therefore, B cells may confer protection after B cell depletion,
but not via a typical Breg IL-10-mediated mechanism, even
though overall anti-CD20 depletion, including depletion of
the IL-10-producing B cells, increases the T cell activation
observed immediately after B cell depletion [5, 14].
However, B cells located in the peritoneum are spared from
depletion [28] and it is known that these cells (B-1) can pro-
duce IL-10 [29]. We did not examine peritoneal B cells, so the
ability of these cells to contribute to regulation of the immune
response cannot be ruled out.
We observed a reduction in both CD86 and CD80 co-
stimulatory molecules upon stimulation, more strikingly with
anti-CD40, during repopulation of B cells in 2H7-treated
mice. Lack of CD86 expression can impair T cell activation,
specifically in NOD mice [30]. Others have shown that
CD80/86 expression on B cells is essential for activating
proteoglycan-specific autoreactive T cells in an arthritic
mouse model [31]. Anti-CD20 B cell depletion influenced
the immunostimulatory environment in the secondary lym-
phoid organs, marked by a reduced expression of
CD86/CD80 along with MHC class II, in a marmoset model
of autoimmune encephalomyelitis [32]. When we examined
regenerated B cells after full repopulation (12 weeks after
depletion), we found no functional difference in the ability
of the B cells from 2H7-treated mice to present insulin-
specific peptide to insulin-specific CD8+ T cells in the prolif-
erative assay that we employed (data not shown). However,
because cells were not tested at an earlier time point during
regeneration, we cannot discount the possibility that lack of
co-stimulatory molecules alters antigen presentation in vivo
during the regeneration period. This is indicated, indirectly, by
the effects observed in the islets.
In human clinical trials, beta cell function is temporarily
preserved after B cell depletion [33] but the effects on pancre-
atic immune cell infiltrate during B cell repopulation cannot
be studied. Our current study showed a 10 week delay in onset
of diabetes, although following extended observation, the end-
point was not statistically significant, in keeping with the hu-
man observations that B cell depletion delays disease
progression. Our current study gives an important insight into
the treatment effects on pancreatic islets, which are ultimately
the target of protection. Interestingly, we showed no enrich-
ment of IL-10 or TGF-β from B cells in the islets of
anti-CD20-treated mice. The IL-10+ B cell population was
downregulated at 12 weeks post treatment but was compara-
ble with that in the control mice long after repopulation.
Overall, the regulatory phenotype of B cells in islets was not
altered by anti-CD20 treatment. Previously, it has been report-
ed that islet B cells become CD20−CD138+ plasma cells after
anti-CD20 treatment [20]. While murine CD20 expression
was not studied here, we demonstrated significant B cell de-
pletion in 12- to 15-week-old mice, which have established
insulitis. CD86/80 expression has been described in the islet B
cells previously, along with the production of TNF-α [34].
Though not specifically addressing the levels of
CD80/CD86 or TNF-α on islet B cells after anti-CD20 treat-
ment, we did not observe any IFN-γ production from either
control IgG- or 2H7-treated mice (data not shown).
B cell depletion affects T cell regulation [5, 14, 35]. No
obvious differences in total T cells were observed, supporting
the human anti-CD20 depletion studies [5]. However, we did
demonstrate that both effector CD4+ and CD8+ islet-
infiltrating T cells were downregulated, including inflamma-
tory IFN-γ production. This supports the notion that B cell
depletion modulates T cell responses [5, 14]. While regulatory
T cells are enriched during B cell repopulation [7, 8], we did
not observe enrichment of IL-10 or TGF-β in islet-infiltrating
cells; in fact IL-10+CD4+ T cells were downregulated. Thus,
local Tregs may operate through IL-10- and TGF-β-
independent mechanisms. In mice, peripheral T cells have
decreased effector cytokines [8] and macrophages from
2H7-treated mice do not present antigen to T cells as efficient-
ly as untreated macrophages [7]. Furthermore, CD11b+GR1+
myeloid-derived suppressor cells are induced post B cell de-
pletion, dependent on a cell–cell contact mechanism indepen-
dent of IL-10 [15]. Here, we show that B cell depletion direct-
ly affects the Tcell composition of the islet infiltrate, long after
the repopulation of B cells, possibly as a result of B cell–
macrophage or B cell–dendritic cell crosstalk occurring direct-
ly in the pancreas.
We speculate that other mechanisms may play a role in the
pancreatic islets. CD44 is an important mediator in inflamma-
tion [36] and anti-CD44 antibody successfully delays the on-
set of diabetes in the NOD mouse [37]. Long after B cell
depletion, decreased CD44 expression on CD8+ T cells may
contribute to the protection seen in B cell-depleted animals,
especially as the ligand for CD44 (hyaluronic acid) is
expressed in islets during inflammation [37]. Furthermore,
we observed an increase in CD69+CD103+CD8+ T cells,
which may be a regulatory CD8+ T cell population in the
islets, long after antibody treatment and B cell repopulation.
This specialised CD8+ T cell (TRM) population, found in
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tissues after viral infections, can control local immunity [38].
It is possible that these cells may also play a role in inflam-
matory disease [25] and autoimmunity. Interestingly, this TRM
population has recently been identified in individuals newly
diagnosed with type 1 diabetes [39].
Our data is consonant with findings made in a small num-
ber of participants in the TrialNet study, showing maintenance
of increased frequencies of autoreactive and polyreactive B
cells before and after anti-B cell therapy (1 year) [6]. Thus,
therapeutic efficacy for the limited time studied was not relat-
ed to maintaining depletion of autoreactive B cells or increase
in regulatory B cell subsets. Anti-B cell therapy with rituxi-
mab is one of the few immunotherapeutic strategies trialled
thus far in humans that has shown transient efficacy in
delaying the decline of C-peptide, along with anti-CD3, anti-
LFA1 and CTLA4-Ig [40–43]. It is likely that more than one
therapeutic strategy will be required for effective immunother-
apy of type 1 diabetes. Ideally, this would encompass agents
with differing mechanisms to complement each other (e.g.
depletion of autoreactive lymphocytes, while increasing en-
dogenous regulation). Our results, indicating that islet-
targeting CD8+ T cells may be more affected by the B cell
treatment, suggest that a potential adjunct therapy to rituximab
could be one that maintains these changes in CD8+ T cells.
In conclusion, we show potential new mechanisms in the
local tissue that may contribute to delay in diabetes onset
following B cell depletion therapy at an early age. Further
investigation is ongoing to dissect these mechanisms, both
during and after B cell depletion. However, a key point is that
removal of B cells alters effector T cells, either directly or
through an antigen-presenting cell population, in the pancre-
atic islets.
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